211 related articles for article (PubMed ID: 8574158)
41. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
Mesa RA; Barosi G; Cervantes F; Reilly JT; Tefferi A
Best Pract Res Clin Haematol; 2006; 19(3):495-517. PubMed ID: 16781486
[TBL] [Abstract][Full Text] [Related]
42. Treatment of thrombocytosis in myeloproliferative disorders with interferon alpha-2a.
Tichelli A; Gratwohl A; Berger C; Lori A; Würsch A; Dieterle A; Thomssen C; Nissen C; Holdener E; Speck B
Blut; 1989 Jan; 58(1):15-9. PubMed ID: 2644994
[TBL] [Abstract][Full Text] [Related]
43. Modern treatment strategies in polycythemia vera.
Gilbert HS
Semin Hematol; 2003 Jan; 40(1 Suppl 1):26-9. PubMed ID: 12682879
[TBL] [Abstract][Full Text] [Related]
44. [Therapy with interferon (recombinant IFN-alpha-2C) in myeloproliferative diseases with severe thrombocytoses].
Linkesch W; Gisslinger H; Ludwig H; Flener R; Sinzinger H
Acta Med Austriaca; 1985; 12(5):123-7. PubMed ID: 3914173
[TBL] [Abstract][Full Text] [Related]
45. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera.
Muller EW; de Wolf JT; Egger R; Wijermans PW; Huijgens PC; Halie MR; Vellenga E
Br J Haematol; 1995 Feb; 89(2):313-8. PubMed ID: 7873381
[TBL] [Abstract][Full Text] [Related]
46. [Therapy of thrombocytosis in myeloproliferative syndromes using recombinant interferon-alpha-2a].
Tichelli A; Gratwohl A; Delacrétaz F; Dazzi H; Stebler C; Wernli M; Holdener EE; Nissen C; Speck B
Schweiz Med Wochenschr; 1989 Sep; 119(39):1347-52. PubMed ID: 2799342
[TBL] [Abstract][Full Text] [Related]
47. Recombinant interferon alpha-2b in the treatment of polycythemia vera.
Cimino R; Rametta V; Matera C; Mele G; Mettivier V; Ferrara F
Am J Hematol; 1993 Nov; 44(3):155-7. PubMed ID: 8213763
[TBL] [Abstract][Full Text] [Related]
48. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.
Gilbert HS
Cancer; 1998 Sep; 83(6):1205-13. PubMed ID: 9740087
[TBL] [Abstract][Full Text] [Related]
49. Pegylated interferon alpha - 2a is clinically effective and tolerable in myeloproliferative neoplasm patients treated off clinical trial.
Gowin K; Jain T; Kosiorek H; Tibes R; Camoriano J; Palmer J; Mesa R
Leuk Res; 2017 Mar; 54():73-77. PubMed ID: 28113109
[TBL] [Abstract][Full Text] [Related]
50. Application of PRV-1 mRNA expression level and JAK2V617F mutation for the differentiating between polycytemia vera and secondary erythrocytosis and assessment of treatment by interferon or hydroxyurea.
Tutaeva V; Misurin AV; Michiels JJ; Rozenberg JM; Sokolova MA; Ivanova VL; Kolosheinova TI; Manakova TE; Levina AA; Semenova EA; Khoroshko ND
Hematology; 2007 Dec; 12(6):473-9. PubMed ID: 17852451
[TBL] [Abstract][Full Text] [Related]
51. The therapy of myelofibrosis: targeting pathogenesis.
Mesa RA
Int J Hematol; 2002 Aug; 76 Suppl 2():296-304. PubMed ID: 12430941
[TBL] [Abstract][Full Text] [Related]
52. Morphology of myeloproliferative neoplasms.
Ng ZY; Fuller KA; Mazza-Parton A; Erber WN
Int J Lab Hematol; 2023 Jun; 45 Suppl 2():59-70. PubMed ID: 37211431
[TBL] [Abstract][Full Text] [Related]
53. The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies.
Kreft A; Büche G; Ghalibafian M; Buhr T; Fischer T; Kirkpatrick CJ
Acta Haematol; 2005; 113(2):137-43. PubMed ID: 15802893
[TBL] [Abstract][Full Text] [Related]
54. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
Michiels JJ
Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
[TBL] [Abstract][Full Text] [Related]
55. Myelofibrosis--what's in a name? Consensus on definition and EUMNET grading.
Thiele J; Kvasnicka HM
Pathobiology; 2007; 74(2):89-96. PubMed ID: 17587880
[TBL] [Abstract][Full Text] [Related]
56. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Passamonti F; Lazzarino M
Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
[TBL] [Abstract][Full Text] [Related]
57. Successful re-treatment of an anti-interferon resistant polycythaemia vera patient with lymphoblastoid interferon-alpha N1 and in vitro studies on the specificity of the antibodies.
Brand CM; Leadbeater L; Budiman R; Lechner K; Gisslinger H
Br J Haematol; 1994 Jan; 86(1):216-8. PubMed ID: 8011536
[TBL] [Abstract][Full Text] [Related]
58. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Hasselbalch HC
Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
[TBL] [Abstract][Full Text] [Related]
59. Complex karyotype in a polycythemia vera patient with a novel SETD1B/GTF2H3 fusion gene.
Tiziana Storlazzi C; Pieri L; Paoli C; Daniele G; Lasho T; Tefferi A; Vannucchi AM
Am J Hematol; 2014 Apr; 89(4):438-42. PubMed ID: 24382738
[TBL] [Abstract][Full Text] [Related]
60. A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia vera.
Sacchi S; Leoni P; Liberati M; Riccardi A; Tabilio A; Tartoni P; Messora C; Vecchi A; Bensi L; Rupoli S
Ann Hematol; 1994 May; 68(5):247-50. PubMed ID: 8018766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
